From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak.

[1]  D. Lennon,et al.  Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  E. Rosenqvist,et al.  Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. , 2009, Vaccine.

[3]  M. Pizza,et al.  Meningococcal protein antigens and vaccines. , 2009, Vaccine.

[4]  K. Mulholland,et al.  Immunogenicity and Tolerability in Infants of a New Zealand Epidemic Strain Meningococcal B Outer Membrane Vesicle Vaccine , 2009, The Pediatric infectious disease journal.

[5]  P. Stehr-Green,et al.  Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. , 2009, International journal of epidemiology.

[6]  D. Levy-bruhl,et al.  Invasive meningococal disease in France, 2009. , 2009 .

[7]  N. Turner,et al.  MeNZB vaccine and epidemic control: when do you stop vaccinating? , 2008, Vaccine.

[8]  A. Zelazny,et al.  Mass antibiotic treatment to stop an outbreak of meningococcal disease: a molecular analysis. , 2007, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[9]  B. Greenwood,et al.  Epidemic meningitis, meningococcaemia, and Neisseria meningitidis , 2007, The Lancet.

[10]  P. Aavitsland,et al.  Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease. , 2007, Vaccine.

[11]  K. Mulholland,et al.  New Zealand Epidemic Strain Meningococcal B Outer Membrane Vesicle Vaccine in Children Aged 16–24 Months , 2007, The Pediatric infectious disease journal.

[12]  E. Rosenqvist,et al.  Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks. , 2007, Vaccine.

[13]  R. Rappuoli,et al.  A universal vaccine for serogroup B meningococcus. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[14]  E. Rosenqvist,et al.  Persisting Immune Responses Indicating Long-Term Protection after Booster Dose with Meningococcal Group B Outer Membrane Vesicle Vaccine , 2006, Clinical and Vaccine Immunology.

[15]  D. Levy-bruhl,et al.  Prolonged outbreak of B meningococcal disease in the Seine-Maritime department, France, January 2003 to June 2005. , 2006, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[16]  R. Rappuoli,et al.  The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease. , 2005, Vaccine.

[17]  M. Taha,et al.  Continuing Diversification of Neisseria meningitidis W135 as a Primary Cause of Meningococcal Disease after Emergence of the Serogroup in 2000 , 2004, Journal of Clinical Microbiology.

[18]  Ying Zhang,et al.  Vaccine Potential of the Neisseria meningitidis 2086 Lipoprotein , 2004, Infection and Immunity.

[19]  E. Rosenqvist,et al.  Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. , 2003, Vaccine.

[20]  T. Popović,et al.  Distribution of Neisseria meningitidisSerogroup B Serosubtypes and Serotypes Circulating in the United States , 2000, Journal of Clinical Microbiology.

[21]  J. Tappero,et al.  Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. , 1999, JAMA.

[22]  A. Leventhal,et al.  Failure of Mass Antibiotic Prophylaxis to Control a Prolonged Outbreak of Meningococcal Disease in an Israeli Village , 1998, European Journal of Clinical Microbiology and Infectious Diseases.

[23]  C. Sacchi,et al.  Specificity of Bactericidal Antibody Response to Serogroup B Meningococcal Strains in Brazilian Children after Immunization with an Outer Membrane Vaccine , 1998, Infection and Immunity.

[24]  E. Rosenqvist,et al.  Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine , 1995, Infection and immunity.

[25]  J. Boslego,et al.  Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. , 1995, Vaccine.

[26]  C. Sacchi,et al.  Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil , 1992, The Lancet.

[27]  G. Bjune,et al.  Results of an efficacy trial with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway. , 1991, NIPH annals.

[28]  A. Lystad,et al.  The epidemiology of meningococcal disease in Norway 1975-91. , 1991, NIPH annals.

[29]  A. Halstensen,et al.  Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway , 1991, The Lancet.

[30]  J. Boslego,et al.  Serotype-specific outbreak of group B meningococcal disease in Iquique, Chile , 1990, Epidemiology and Infection.

[31]  P. Weihe,et al.  An epidemic outbreak of group B meningococcal disease on the Faroe Islands. , 1988, Scandinavian journal of infectious diseases.

[32]  H. Zanen,et al.  MENINGOCOCCAL SEROTYPES AND SEROGROUP B DISEASE IN NORTH-WEST EUROPE , 1986, The Lancet.

[33]  B Bégaud,et al.  Imputabilité des effets inattendus ou toxiques des médicaments: actualisation de la méthode utilisée en France , 1985 .